🍽️ urosiol,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Gallstone Dissolution: Ursodiol works by decreasing the production of cholesterol and by dissolving cholesterol-containing gallstones, which can help alleviate symptoms associated with gallstones and prevent complications such as gallbladder inflammation (cholecystitis) or blockage of the bile ducts.

  2. Prevention of Gallstone Formation: Ursodiol can also be used to prevent the formation of new gallstones in patients who are at high risk, such as those who have undergone bariatric surgery or who have rapid weight loss.

  3. Treatment of Primary Biliary Cholangitis (PBC): Ursodiol is a first-line treatment for PBC, a chronic autoimmune liver disease that damages the bile ducts in the liver. Ursodiol helps improve liver function tests and may slow the progression of the disease, although it does not cure PBC.

  4. Side Effects: Common side effects of ursodiol may include diarrhea, upset stomach, nausea, vomiting, and abdominal pain. These side effects are usually mild and may improve over time as the body adjusts to the medication. However, if these side effects persist or worsen, it's important to consult a healthcare professional.

  5. Contraindications: Ursodiol is contraindicated in patients with certain conditions, such as complete biliary obstruction, acute cholecystitis, and pancreatitis. It should also be used with caution in patients with liver or gallbladder disease, kidney disease, or a history of gallstones.

  6. Monitoring: Patients taking ursodiol may require regular monitoring of liver function tests and ultrasound imaging to assess the effectiveness of treatment and to detect any potential complications.

  7. Interactions: Ursodiol may interact with other medications, such as antacids containing aluminum, cholesterol-lowering medications (e.g., cholestyramine), and certain immunosuppressive drugs. It's important to inform your healthcare provider about all medications, supplements, and herbal products you are taking before starting ursodiol treatment.

  8. Pregnancy and Breastfeeding: Ursodiol is generally considered safe to use during pregnancy and breastfeeding, but pregnant or breastfeeding women should consult their healthcare provider before taking any medication.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of urosiol,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by urosiol,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Escherichia genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Streptococcus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Parabacteroides distasonis species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
[Ruminococcus] gnavus species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Roseburia intestinalis species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of urosiol,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.3 0.3
ADHD 0.8 0.8
Age-Related Macular Degeneration and Glaucoma 0.1 0.3 -2
Allergic Rhinitis (Hay Fever) 1.2 1.2
Allergies 0.9 0.3 2
Allergy to milk products 0.8 0.6 0.33
Alopecia (Hair Loss) 0.7 0.7
Alzheimer's disease 2.1 1 1.1
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.5 0.7 -0.4
Ankylosing spondylitis 2.4 0.8 2
Anorexia Nervosa 0.3 0.2 0.5
Antiphospholipid syndrome (APS) 1.3 0.3 3.33
Asthma 0.2 -0.2
Atherosclerosis 0.3 0.4 -0.33
Atrial fibrillation 0.6 1.3 -1.17
Autism 2.4 2 0.2
Barrett esophagus cancer 0.3 0.3 0
benign prostatic hyperplasia 0.4 0.4
Bipolar Disorder 1 0.1 9
Brain Trauma 0.2 -0.2
Cancer (General) 0.3 -0.3
Carcinoma 1.3 0.3 3.33
Celiac Disease 1.1 0.7 0.57
Cerebral Palsy 0.3 0.2 0.5
Chronic Fatigue Syndrome 2.4 2.1 0.14
Chronic Kidney Disease 1.2 0.1 11
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 1.6 0.1 15
Chronic Urticaria (Hives) 1.4 0.5 1.8
Coagulation / Micro clot triggering bacteria 1.6 0.4 3
Colorectal Cancer 3.5 3.5
Constipation 0.5 0.1 4
Coronary artery disease 0.5 0.5
COVID-19 2.5 2.1 0.19
Crohn's Disease 3.6 0.9 3
cystic fibrosis 1.1 0.2 4.5
deep vein thrombosis 1.1 0.4 1.75
Depression 3.5 1.8 0.94
Dermatomyositis 0.3 0.3
Eczema 0.8 1.3 -0.63
Endometriosis 1.7 1.7
Eosinophilic Esophagitis 0.3 0.3
Epilepsy 1.2 0.7 0.71
Fibromyalgia 0.8 0.5 0.6
Functional constipation / chronic idiopathic constipation 1.9 0.7 1.71
gallstone disease (gsd) 0.6 0.4 0.5
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.5 0.3 0.67
Generalized anxiety disorder 1.9 0.1 18
Glioblastoma 0.3 -0.3
Graves' disease 0.3 0.1 2
Halitosis 0.4 0.3 0.33
Hashimoto's thyroiditis 0.2 0.4 -1
Hidradenitis Suppurativa 0.9 0.9
Histamine Issues 1 0.2 4
hyperglycemia 0.4 0.3 0.33
hypersomnia 0.3 -0.3
hypertension (High Blood Pressure 1 1 0
Hypoxia 0.3 0.3
IgA nephropathy (IgAN) 0.9 -0.9
Inflammatory Bowel Disease 2.9 1.7 0.71
Insomnia 0.3 0.2 0.5
Intelligence 0.1 0.3 -2
Intracranial aneurysms 0.3 0.3
Irritable Bowel Syndrome 1.3 0.7 0.86
Liver Cirrhosis 1.7 0.8 1.13
Long COVID 2 1.1 0.82
Low bone mineral density 0.1 -0.1
Lung Cancer 0.4 0.4
Mast Cell Issues / mastitis 0.6 0.6
ME/CFS with IBS 0.5 0.1 4
ME/CFS without IBS 0.8 0.8 0
Metabolic Syndrome 3.1 1.7 0.82
Mood Disorders 3.8 1.8 1.11
multiple chemical sensitivity [MCS] 1.1 1.1
Multiple Sclerosis 2.2 1.9 0.16
Multiple system atrophy (MSA) 0.2 0.2
neuropathic pain 0.1 -0.1
Neuropathy (all types) 0.3 0.4 -0.33
neuropsychiatric disorders (PANDAS, PANS) 0.7 0.7
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.9 0.1 8
Obesity 1.9 1.8 0.06
obsessive-compulsive disorder 2.1 0.8 1.63
Osteoarthritis 1.2 1.2
Osteoporosis 0.4 0.1 3
pancreatic cancer 0.3 0.3
Parkinson's Disease 1.6 1.5 0.07
Polycystic ovary syndrome 0.8 0.1 7
Premenstrual dysphoric disorder 0.3 -0.3
primary biliary cholangitis 0.1 -0.1
Psoriasis 1.2 1.5 -0.25
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.8 0.7 3
Rosacea 0.1 -0.1
Schizophrenia 0.8 0.1 7
scoliosis 0.3 -0.3
Sjögren syndrome 1.2 0.5 1.4
Sleep Apnea 0.3 0.2 0.5
Small Intestinal Bacterial Overgrowth (SIBO) 1.3 1.3
Stress / posttraumatic stress disorder 1.5 0.2 6.5
Systemic Lupus Erythematosus 2.2 0.1 21
Tic Disorder 0 0.3 0
Tourette syndrome 0.1 -0.1
Type 1 Diabetes 1 0.4 1.5
Type 2 Diabetes 3.1 2.1 0.48
Ulcerative colitis 1.6 1.3 0.23
Unhealthy Ageing 2.4 0.1 23

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [34.239.170 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.239.170 ]